WO1999058123A3 - Novel fatty acid analogues for the treatment of primary and secondary restenosis - Google Patents

Novel fatty acid analogues for the treatment of primary and secondary restenosis Download PDF

Info

Publication number
WO1999058123A3
WO1999058123A3 PCT/NO1999/000149 NO9900149W WO9958123A3 WO 1999058123 A3 WO1999058123 A3 WO 1999058123A3 NO 9900149 W NO9900149 W NO 9900149W WO 9958123 A3 WO9958123 A3 WO 9958123A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
primary
fatty acid
acid analogues
novel fatty
Prior art date
Application number
PCT/NO1999/000149
Other languages
French (fr)
Other versions
WO1999058123A2 (en
Inventor
Rolf Berge
Original Assignee
Thia Medica As
Rolf Berge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ508046A priority Critical patent/NZ508046A/en
Application filed by Thia Medica As, Rolf Berge filed Critical Thia Medica As
Priority to US09/674,982 priority patent/US6417232B1/en
Priority to CA002331393A priority patent/CA2331393C/en
Priority to AU54517/99A priority patent/AU761355B2/en
Priority to DE69927805T priority patent/DE69927805T2/en
Priority to AT99940723T priority patent/ATE306916T1/en
Priority to JP2000547974A priority patent/JP4465672B2/en
Priority to EP99940723A priority patent/EP1075260B1/en
Publication of WO1999058123A2 publication Critical patent/WO1999058123A2/en
Publication of WO1999058123A3 publication Critical patent/WO1999058123A3/en
Priority to NO20005463A priority patent/NO20005463L/en
Priority to HK01105689A priority patent/HK1034911A1/en
Priority to US10/151,203 priority patent/US7026356B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention relates to novel fatty acid analogues of the general formula (I): CH3 -[CH2]m - [xi - CH2]n - COOR, wherein n is an integer from 1 to 12, and wherein m is an integer from 0 to 23, and wherein i is an odd number which indicates the position relative to COOR, and wherein Xi independent of each other are selected from the group comprising O, S, SO, SO2, Se and CH2, and wherein R represents hydrogen or C1-C4 alkyl, with the proviso that at least one of the Xi is not CH2, or a salt, prodrug or complex thereof, for the preparation of a pharmaceutical composition for the treatment and/or prevention of primary and/or secondary stenosis. Further the present invention relates to the use of said compounds for the prevention and/or treatment of a disease caused by procedural vascular trauma and/or pathological proliferation of smooth muscle cells, and/or an increased level of plasma homocysteine.
PCT/NO1999/000149 1998-05-08 1999-05-07 Novel fatty acid analogues for the treatment of primary and secondary restenosis WO1999058123A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AT99940723T ATE306916T1 (en) 1998-05-08 1999-05-07 NEW FAT ANALOGUES FOR THE TREATMENT OF SECONDARY RESTENOSIS
US09/674,982 US6417232B1 (en) 1998-05-08 1999-05-07 Fatty acid analogues for the treatment of primary and secondary restenosis
CA002331393A CA2331393C (en) 1998-05-08 1999-05-07 Fatty acid analogues for the treatment of primary and secondary restenosis
AU54517/99A AU761355B2 (en) 1998-05-08 1999-05-07 Novel fatty acid analogues for the treatment of primary and secondary restenosis
DE69927805T DE69927805T2 (en) 1998-05-08 1999-05-07 NEW FAT ANALOGUE FOR THE TREATMENT OF SECONDARY RESTENOSIS
NZ508046A NZ508046A (en) 1998-05-08 1999-05-07 Fatty acid analogues for the treatment of primary and secondary restenosis
JP2000547974A JP4465672B2 (en) 1998-05-08 1999-05-07 Pharmaceutical composition for the treatment and / or prevention of restenosis and use of TTA for preparing it
EP99940723A EP1075260B1 (en) 1998-05-08 1999-05-07 Novel fatty acid analogues for the treatment of secondary restenosis
NO20005463A NO20005463L (en) 1998-05-08 2000-10-30 New fatty acid analogues for the treatment of primary and secondary restenosis
HK01105689A HK1034911A1 (en) 1998-05-08 2001-08-14 Novel fatty acid analogues for the treatment of secondary restenosis
US10/151,203 US7026356B2 (en) 1998-05-08 2002-05-17 Fatty acid analogues for the treatment of diseases caused by the pathological proliferation of smooth muscle cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
NOPCT/NO98/00143 1998-05-08

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09/674,982 A-371-Of-International US6417232B1 (en) 1998-05-08 1999-05-07 Fatty acid analogues for the treatment of primary and secondary restenosis
US09674982 A-371-Of-International 1999-05-07
US10/151,203 Division US7026356B2 (en) 1998-05-08 2002-05-17 Fatty acid analogues for the treatment of diseases caused by the pathological proliferation of smooth muscle cells

Publications (2)

Publication Number Publication Date
WO1999058123A2 WO1999058123A2 (en) 1999-11-18
WO1999058123A3 true WO1999058123A3 (en) 2000-03-09

Family

ID=19907879

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
PCT/NO1999/000136 WO1999058122A1 (en) 1998-05-08 1999-04-23 Novel fatty analogues for the treatment of diabetes
PCT/NO1999/000135 WO1999058121A1 (en) 1998-05-08 1999-04-23 Novel fatty analogues for the treatment of obesity, hypertension and fatty liver
PCT/NO1999/000149 WO1999058123A2 (en) 1998-05-08 1999-05-07 Novel fatty acid analogues for the treatment of primary and secondary restenosis

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
PCT/NO1999/000136 WO1999058122A1 (en) 1998-05-08 1999-04-23 Novel fatty analogues for the treatment of diabetes
PCT/NO1999/000135 WO1999058121A1 (en) 1998-05-08 1999-04-23 Novel fatty analogues for the treatment of obesity, hypertension and fatty liver

Country Status (18)

Country Link
US (4) US6365628B1 (en)
EP (5) EP1075258B1 (en)
JP (3) JP2002514595A (en)
KR (3) KR100701502B1 (en)
CN (3) CN1245157C (en)
AT (5) ATE247464T1 (en)
AU (4) AU7240398A (en)
BR (2) BR9910296A (en)
CA (3) CA2331395C (en)
DE (5) DE69909775T2 (en)
DK (3) DK1075259T3 (en)
ES (3) ES2204142T3 (en)
HK (3) HK1034911A1 (en)
NO (3) NO20005461L (en)
NZ (3) NZ508045A (en)
PT (2) PT1075259E (en)
RU (3) RU2219920C2 (en)
WO (4) WO1999058120A1 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
JP2003514855A (en) * 1999-10-13 2003-04-22 チャコン，マルコ，エー． Therapeutic intervention mimicking the effects of calorie restriction
NO328803B1 (en) * 2000-03-03 2010-05-18 Thia Medica New fatty acid analogues
NO20003591L (en) * 2000-07-13 2002-01-14 Thia Medica As Fatty acid analogues for the treatment of cancer
NO20006008L (en) 2000-11-28 2002-05-29 Thia Medica As Fatty acid analogues for the treatment of inflammatory and autoimmune diseases
DE10115740A1 (en) * 2001-03-26 2002-10-02 Ulrich Speck Preparation for restenosis prophylaxis
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
SI1547614T1 (en) * 2002-05-28 2011-04-29 Ajinomoto Kk Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof
RU2331649C2 (en) * 2002-06-20 2008-08-20 Ай-Си Ви-И-Си Лимитед Sulphur containing phospholipid derivatives, pharmaceutical compositions containing them, their use in treating diseases and method of obtaining them
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
KR20050033662A (en) 2002-09-06 2005-04-12 얀센 파마슈티카 엔.브이. Heterocyclic compounds
AU2003272738B2 (en) * 2002-09-27 2010-04-01 Martek Biosciences Corporation Docosahexaenoic acid for improved glycemic control
NZ539106A (en) * 2002-10-10 2007-02-23 Yeda Res & Dev Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
FR2850650B1 (en) * 2003-01-31 2005-03-25 Genfit S A THERAPEUTIC USE OF ACYLGLYCEROLS AND THEIR NITROGEN AND SULFUR ANALOGUES
FR2850869B1 (en) * 2003-02-12 2005-03-25 Genfit S A USES OF ACYLATED AMINOPROPANEDIOLS AND THEIR NITROGEN AND SULFUR ANALOGUES
CA2515368A1 (en) 2003-02-13 2004-08-26 Luciano Rossetti Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
US20090215895A1 (en) * 2004-01-30 2009-08-27 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
WO2005119250A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. New intravenous drug administration and blood sampling model in the awake rat
DE102004034640A1 (en) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Method for systemic biocorrection of an organism
ES2660700T3 (en) * 2004-07-19 2018-03-23 Bergen Teknologioverføring As Composition comprising vegetable and / or fish oils and non-oxidizable fatty acid entities
NO324534B1 (en) * 2004-07-19 2007-11-19 Thia Medica As Material prepared from a combination of non-β-oxidizable fatty acid analogues and a plant oil or fish oil and uses thereof
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
WO2006083439A2 (en) * 2004-12-28 2006-08-10 The Research Foundation Of State University Of New York At Buffalo Method for lowering serum homocysteine
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
WO2006117664A1 (en) * 2005-05-04 2006-11-09 Pronova Biopharma Norge As New dha derivatives and their use as medicaments
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (en) * 2005-07-18 2007-01-19 Thia Medica As Use of compounds comprising fatty acids
NO20055541L (en) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
BRPI0718420A2 (en) 2006-10-20 2013-11-12 Cpd Llc RESEARCH METHOD OF INCRETIN EFFECT
CA2667150A1 (en) * 2006-11-01 2008-11-06 Pronova Biopharma Norge As Omega-3 lipid compounds
CA2667211A1 (en) * 2006-11-01 2008-05-08 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar)
US20080221115A1 (en) * 2007-02-26 2008-09-11 Liat Hayardeny-Nisimov Use of long-chain alcohol derivatives for the treatment of alopecia areata
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
CA2702577A1 (en) 2007-10-15 2009-04-23 Jbs United, Inc. Method for increasing performance of offspring
KR20100100818A (en) * 2007-10-31 2010-09-15 프로노바 바이오파마 노르지 에이에스 New dha derivatived and their use as medicaments
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
RU2502727C2 (en) * 2008-04-29 2013-12-27 Ф.Хоффманн-Ля Рош Аг 4-trimethylammonio-butyrates as cpt2 inhibitors
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (en) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc Solute concentration measurement device and related methods
PT2427415T (en) 2009-05-08 2019-05-31 Basf As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
CA2921304C (en) 2009-07-30 2018-06-05 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN103237546B (en) 2010-07-28 2016-06-08 生命科技公司 The antiviral compound that contains azide
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
KR102265409B1 (en) 2010-11-05 2021-06-16 바스프 에이에스 Methods of treatment using lipid compounds
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
KR102213143B1 (en) 2013-02-28 2021-02-08 바스프 에이에스 A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
CA2904898C (en) 2013-03-11 2019-10-15 Jan Remmereit Lipid compositions containing bioactive fatty acids
WO2014140934A2 (en) 2013-03-11 2014-09-18 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (en) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Method of treatment of acute hepatosis in cats
ES2787223T3 (en) 2014-11-07 2020-10-15 Univ Minnesota Salts and compositions useful for treating diseases
AU2016256552B2 (en) 2015-04-28 2021-04-01 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
JP7312184B2 (en) * 2017-10-23 2023-07-20 エピトラッカー インコーポレイテッド Fatty acid analogues and their use in treating symptoms associated with metabolic syndrome
US11925614B2 (en) 2017-12-06 2024-03-12 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
JP7404382B2 (en) * 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド Fatty acid analogs and their use in the treatment of cognitive dysfunction, behavioral symptoms and chronic pain

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345038A2 (en) * 1988-06-02 1989-12-06 Norsk Hydro A/S Non-beta-oxidizable fatty acid analogues with the effect to reduce the concentration of cholesterol and triglycerides in blood of mammals
WO1997003663A1 (en) * 1995-07-14 1997-02-06 Rolf Berge NON-β-OXIDIZABLE FATTY ACID ANALOGUES, THEIR USES AS THERAPEUTIC ACTIVE MEDICAMENTS, AND PREPARATION THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (en) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd Vessel strengthening agent
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
WO1996040098A2 (en) * 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
ATE221324T1 (en) * 1996-11-20 2002-08-15 Nutricia Nv FAT-CONTAINING NUTRITIONAL COMPOSITION FOR THE TREATMENT OF METABOLIC SYNDROME
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345038A2 (en) * 1988-06-02 1989-12-06 Norsk Hydro A/S Non-beta-oxidizable fatty acid analogues with the effect to reduce the concentration of cholesterol and triglycerides in blood of mammals
WO1997003663A1 (en) * 1995-07-14 1997-02-06 Rolf Berge NON-β-OXIDIZABLE FATTY ACID ANALOGUES, THEIR USES AS THERAPEUTIC ACTIVE MEDICAMENTS, AND PREPARATION THEREOF

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOCHEM. BIOPHYS. ACTA., vol. 1300, no. 2, 1996, pages 86 - 96 *
E. DYROY ET AL.: "The Influence of a Novel Antioxidant Fatty Acid on the Development of Stenosis After Ballon Injury", LIPIDS,, vol. 34, 1999, pages 339 *
STN INTERNATIONAL, File CAPLUS, CAPLUS Accession No. 1996:312821, Document No. 125:75989, ASIEDU DANIEL K. et al., "long- term effect of tetradecylthioacetic acid: a study on plasma lipid profile and fatty composition and oxidation in different rat organs". *

Also Published As

Publication number Publication date
ATE306916T1 (en) 2005-11-15
US6365628B1 (en) 2002-04-02
AU4936699A (en) 1999-11-29
HK1034911A1 (en) 2001-11-09
CN1244323C (en) 2006-03-08
KR100701502B1 (en) 2007-04-02
CA2331408C (en) 2008-10-21
NO20005463D0 (en) 2000-10-30
AU762792B2 (en) 2003-07-03
NO20005463L (en) 2001-01-08
CA2331393A1 (en) 1999-11-18
RU2223095C2 (en) 2004-02-10
DE69932864D1 (en) 2006-09-28
CA2331393C (en) 2009-08-11
ATE245416T1 (en) 2003-08-15
JP5057003B2 (en) 2012-10-24
JP4465672B2 (en) 2010-05-19
AU5451799A (en) 1999-11-29
WO1999058121A1 (en) 1999-11-18
KR20010043316A (en) 2001-05-25
DK1075260T3 (en) 2006-02-06
CN1302204A (en) 2001-07-04
ES2204142T3 (en) 2004-04-16
EP1075258A1 (en) 2001-02-14
KR20010043314A (en) 2001-05-25
CA2331395A1 (en) 1999-11-18
WO1999058123A2 (en) 1999-11-18
EP1075260A2 (en) 2001-02-14
AU7240398A (en) 1999-11-29
JP2002514595A (en) 2002-05-21
DE69909775T2 (en) 2004-06-03
AU762790B2 (en) 2003-07-03
EP1075259B1 (en) 2003-07-23
DK1075259T3 (en) 2003-11-03
NO20005461L (en) 2001-01-08
PT1075259E (en) 2003-12-31
WO1999058120A1 (en) 1999-11-18
DE69910559T2 (en) 2004-06-17
US7026356B2 (en) 2006-04-11
NO20005461D0 (en) 2000-10-30
NZ508045A (en) 2003-08-29
EP1075258B1 (en) 2003-08-20
KR20010043315A (en) 2001-05-25
AU761355B2 (en) 2003-06-05
BR9910296A (en) 2002-01-15
KR100701503B1 (en) 2007-04-02
AU4936799A (en) 1999-11-29
EP1285652A1 (en) 2003-02-26
US20020198259A1 (en) 2002-12-26
EP1075260B1 (en) 2005-10-19
HK1034912A1 (en) 2001-11-09
ATE247464T1 (en) 2003-09-15
BR9910297A (en) 2002-01-02
ES2207253T3 (en) 2004-05-16
DE69932645D1 (en) 2006-09-14
EP1075259A1 (en) 2001-02-14
HK1034909A1 (en) 2001-11-09
KR100822077B1 (en) 2008-04-14
DE69910559D1 (en) 2003-09-25
ATE336239T1 (en) 2006-09-15
CA2331395C (en) 2008-10-14
NZ508046A (en) 2003-08-29
RU2221558C2 (en) 2004-01-20
WO1999058122A1 (en) 1999-11-18
DK1075258T3 (en) 2003-12-01
DE69927805T2 (en) 2006-07-06
PT1075258E (en) 2004-01-30
NO333143B1 (en) 2013-03-18
CN1223343C (en) 2005-10-19
CN1245157C (en) 2006-03-15
RU2219920C2 (en) 2003-12-27
CA2331408A1 (en) 1999-11-18
US6441036B1 (en) 2002-08-27
CN1300212A (en) 2001-06-20
ATE334666T1 (en) 2006-08-15
NO20005462D0 (en) 2000-10-30
DE69927805D1 (en) 2006-03-02
EP1285652B1 (en) 2006-08-16
JP2002514596A (en) 2002-05-21
NO20005462L (en) 2001-01-08
JP2002514594A (en) 2002-05-21
NZ508047A (en) 2003-05-30
DE69909775D1 (en) 2003-08-28
EP1284139B1 (en) 2006-08-02
US6417232B1 (en) 2002-07-09
EP1284139A1 (en) 2003-02-19
ES2251218T3 (en) 2006-04-16
CN1300211A (en) 2001-06-20

Similar Documents

Publication Publication Date Title
WO1999058123A3 (en) Novel fatty acid analogues for the treatment of primary and secondary restenosis
IL115746A (en) Polyanionic benzylglcosides and pharmaceutical compositions containing them
GR3029603T3 (en) Cytotoxic stilbene derivatives and pharmaceutical composition containing them.
IL216046A0 (en) Fused compounds containing an ureido group that inhibit vanilloid receptor subtype 1 (vr1) receptor ,for treating disorders caused by vanilloid receptor activity and process for their preparation
MY117290A (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
RU2000131220A (en) NEW ANALOGUES OF FATTY ACIDS FOR TREATMENT OF PRIMARY AND SECONDARY RESTENOSIS
CA2153979A1 (en) Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
DK0494071T3 (en)
IL102758A0 (en) Glycosaminoglycanoid derivatives,their preparation and pharmaceutical compositions comprising them
AU552908B2 (en) 4 n-phenyl benzyl-aminomethyl-imidazole
GB2434582A (en) Thermosensitive and biocompatible amphiphilic poly(organophosphazenes) and preparation method thereof
ES483289A1 (en) 1,2,3,5-Tetrahydroimidazothienopyrimidin-2-ones, a process for their preparation and pharmaceutical compositions.
WO2001042262A3 (en) Antithrombotic compound
EP0178178A3 (en) Purine derivatives
IL115747A (en) Polyanionic benzylglycosides of benzene triacid amides and pharmaceutical compositions containing them
WO1999003817A3 (en) Aliphatic propargylamines as cellular rescue agents
WO2003033506A1 (en) Aminoborane acid derivative and proteasome inhibitory drug containing the same
ES480041A1 (en) Pharmaceutically active cyclohexyl compounds and their preparation
IE43009L (en) Sulfonamides.
WO2000031094A3 (en) Benzylglycosylamides as inhibitors of smooth muscle cell proliferation
JP2004504399A5 (en)
CA2310055A1 (en) New urethanes, the thio and dithio analogues thereof,the salts thereof, pharmaceutical compositions containing these compounds and their use as well as process for preparing them
ES485333A1 (en) 5,6,7,8-Tetrahydro-4(3H)- quinazolinone derivatives useful as spasmolytics
ATE58730T1 (en) BENZOXATHIIN DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS.
TH54859A3 (en) Non-steroidal anti-inflammatory agents

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99805967.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2331393

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020007012283

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 508046

Country of ref document: NZ

Ref document number: IN/PCT/2000/623/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1999940723

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 54517/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 09674982

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999940723

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007012283

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 54517/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999940723

Country of ref document: EP